Illumina, Inc. vs Williams-Sonoma, Inc. — how do they compare? Illumina, Inc. trades at $274.99 (market cap $39.95B), while Williams-Sonoma, Inc. trades at $241.67 (market cap $28.15B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Williams-Sonoma, Inc. for 59 Days on average.
| ILMN | WSM | |
|---|---|---|
Market Cap | $39.95B | $28.15B |
Volume | 3,169,503 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $251.81 |
52-Week Low | $91.00 | $168.64 |
Typical Hold Time | 83 Days | 59 Days |
Enterprise Value | $41.31B | $28.65B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high return on equity of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook remains positive with a consensus price target of $246.31, suggesting moderate upside. Key opportunities include sustained margin strength and digital initiatives, while risks involve housing market sensitivity and competitive pressures. Institutional sentiment is mixed with 32% buy ratings, but recent insider selling by the CFO warrants monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →